Table 3 Paired samples t-test of medication percentage reduction in comparison to baseline divided into groups A and B and subgroups throughout the follow up period
From: Ab externo canaloplasty results and efficacy: a retrospective cohort study with a 12-month follow-up
Group A – Medication %↓ Advanced POAG | n | Mean | Range | SD | Different (P < 0.05) from factor nr |
(1) A) Baseline | 172 | 0.00 | 0.0 | ±0.00 | (2)(3)(4)(5)(6)(7) |
(2) B) 1 Day | 172 | − 100.00 | −100.0 / -100.0 | ±0.00 | (1)(3)(4)(5)(6)(7) |
(3) C) 2 Weeks | 171 | −93.59 | −100.0 / + 50.0 | ±19.94 | (1)(2) |
(4) D) 1 Month | 161 | −90.38 | −100.0 / + 50.0 | ±26.26 | (1)(2) |
(5) E) 3 Months | 155 | −89.60 | −100.0 / + 50.0 | ±29.68 | (1)(2) |
(6) F) 6 Months | 151 | −89.40 | −100.0 / -100.0 | ±33.84 | (1)(2) |
(7) G) 12 Months | 168 | −91.43 | −100.0 / + 66.0 | ±30.74 | (1)(2) |
Group B - Medication %↓ Advanced POAG | n | Mean | Range | SD | Different (P < 0.05) from factor nr |
(1) A) Baseline | 212 | 0.00 | 0,0 | ±0.00 | (2)(3)(4)(5)(6)(7) |
(2) B) 1 Day | 212 | −99.90 | −100.0 / -80.0 | ±1.37 | (1)(3)(5)(6)(7) |
(3) C) 2 Weeks | 187 | −95.56 | −100.0 / + 33.0 | ±18.37 | (1)(2)(7) |
(4) D) 1 Month | 173 | −97.56 | −100.0 / 0.0 | ±15.48 | (1)(7) |
(5) E) 3 Months | 134 | −95.83 | −100.0 / 0.0 | ±15.85 | (1)(2) |
(6) F) 6 Months | 132 | −93.78 | −100.0 / 0.0 | ±21.28 | (1)(2) |
(7) G) 12 Months | 168 | −89.43 | −100.0 / 00 | ±29.28 | (1)(2)(3)(4) |
Group A - Medication %↓ Moderate POAG | n | Mean | Range | SD | Different (P < 0.05) from factor nr |
(1) A) Baseline | 51 | 0.00 | 0.0 | ±0.00 | (2)(3)(4)(5)(6)(7) |
(2) B) 1 Day | 51 | −100.00 | −100.0 / -100.0 | ±0.00 | (1)(7) |
(3) C) 2 Weeks | 50 | −95.45 | −100.0 / -33.0 | ±15.17 | (1)(7) |
(4) D) 1 Month | 48 | −95.28 | − 100.0 / -33.0 | ±15.46 | (1)(7) |
(5) E) 3 Months | 41 | −96.55 | −100.0 / 0.0 | ±18.56 | (1)(7) |
(6) F) 6 Months | 39 | −95.96 | −100.0 / -66.0 | ±10.73 | (1)(7) |
(7) G) 12 Months | 48 | −76.66 | −100.0 / + 100.0 | ±55.51 | (1)(2)(3)(4)(5)(6) |
Group B - Medication %↓ Moderate POAG | n | Mean | Range | SD | Different (P < 0.05) from factor nr |
(1) A) Baseline | 75 | 0.00 | 0.0 | ±0.00 | (2)(3)(4)(5)(6)(7) |
(2) B) 1 Day | 75 | −100.00 | −100.0 / -100.0 | ±0.00 | (1)(7) |
(3) C) 2 Weeks | 68 | −96.54 | −100.0 / -50.0 | ±12.38 | (1)(7) |
(4) D) 1 Month | 60 | −94.14 | −100.0 / 0.0 | ±19.42 | (1)(7) |
(5) E) 3 Months | 55 | −94.30 | −100.0 / 0.0 | ±22.23 | (1)(7) |
(6) F) 6 Months | 49 | −98.48 | −100.0 / -66.0 | ±7.10 | (1)(7) |
(7) G) 12 Months | 63 | −84.21 | −100.0 / 0.0 | ±34.00 | (1)(2)(3)(4)(5)(6) |
Group A - Medication %↓ Early POAG | n | Mean | Range | SD | Different (P < 0.05) from factor nr |
(1) A) Baseline | 39 | 0.00 | 0.0 | ±0.00 | (2)(3)(4)(5)(6)(7) |
(2) B) 1 Day | 39 | −96.15 | −100.0 / + 50.0 | ±24.01 | (1)(5)(7) |
(3) C) 2 Weeks | 39 | −92.85 | −100.0 / -50.0 | ±15.43 | (1) |
(4) D) 1 Month | 34 | −86.76 | −100.0 / 0.0 | ±28.72 | (1) |
(5) E) 3 Months | 35 | −72.77 | −100.0 / + 100.0 | ±50.58 | (1)(2) |
(6) F) 6 Months | 26 | −77.17 | −100.0 / -20.0 | ±33.04 | (1) |
(7) G) 12 Months | 30 | −65.15 | −100.0 / + 50.0 | ±50.80 | (1)(2) |
Group B - Medication %↓ Early POAG | n | Mean | Range | SD | Different (P < 0.05) from factor nr |
(1) A) Baseline | 35 | 0.00 | 0,0 | ±0.00 | (2)(3)(4)(5)(6)(7) |
(2) B) 1 Day | 35 | −100.00 | −100.0 / -100.0 | ±0.00 | (1)(5) |
(3) C) 2 Weeks | 30 | −100.00 | −100.0 / -100.0 | ±0.00 | (1)(5) |
(4) D) 1 Month | 24 | −100.00 | −100.0 / -100.0 | ±0.00 | (1)(5) |
(5) E) 3 Months | 26 | −95.00 | −100.0 / -50.0 | ±15.38 | (1)(2)(3)(4)(6)(7) |
(6) F) 6 Months | 28 | −100.00 | −100.0 / -100.0 | ±0.00 | (1)(5) |
(7) G) 12 Months | 29 | −100.00 | −100.0 / -100.0 | ±0.00 | (1)(5) |